COMBINATION THERAPY OF HIGH-RISK PATIENTS IN REAL CLINICAL PRACTICE. RESULTS OF SYNERGY STUDY. PART 1. ANTIHYPERTENSIVE BRANCH

Aim. To study the efficacy and safety of the use of combined antihypertensive therapy with perindopril (as monotherapy or as a fixed combination with amlodipine or indapamide) together with lipid-lowering therapy with rosuvastatin, and to assess the level of satisfaction of doctors with the efficacy and safety of these combinations. Material and methods. 24 008 patients with arterial hypertension (HT) and dyslipidemia were included into the multicentre observational study. Researchers were free to choose a group of drugs and a prescription schedule. Inclusion criteria: age ≥18 years; the confirmed HT; combined therapy, including perindopril (monotherapy or fixed combination with indapamide or amlodipine) and rosuvastatin. The total duration of the study was 8 months (2 visits). At each visit, all patients underwent an office blood pressure (BP) and heart rate (HR) measurement, electrocardiogram registration, and assessment of lipids, electrolytes, creatinine, uric acid blood concentrations, and hepatic transaminase activity. Results. 10 330 men (43%) and 13 678 women (57%) were included into the study. The mean age of the patients was 61.83Ѓ}11.20 years. Ischemic heart disease was found in 9 792 (41%) patients, the history of myocardial infarction – in 12%, the history of stroke – in 6%, atrial fibrillation – in 2 428 (10%), chronic heart failure – in 15 449 (64%), diabetes mellitus – in 6 037 (25%) patients. Previous antihypertensive therapy was not available in 2 504 patients. A significant decrease in systolic and diastolic BP, HR was detected at visit 2 in patients using perindopril containing drugs (monodrug, fixed combinations with indapamide or amlodipine). Target systolic BP levels were achieved in 95% of patients with perindopril monotherapy, in 91% – with a fixed combination of perindjpril/indapamide, and in 88.6% – with perindopril/amlodipine. Doctors noted high satisfaction with the therapy. According to safety assessment the average score for perindopril monotherapy was 9.64, for a fixed combination of perindopril/indapamide – 9.61, for a fixed combination of perindopril/amlodipine – 9.64. Conclusion. Some aspects of the efficacy and safety of antihypertensive therapy in the SYNERGY study are discussed in this article. The use of combination therapy is associated with high efficacy, greater patient adherence to treatment and a lower incidence of discontinuation. All these provisions were confirmed in the SYNERGY study.

1. Drapkina O.M., Korneeva O.N., Zyatenkova E.V., et al. Rosuvastatin in patients with arterial hypertension and dyslipidemia: effect on microcirculation and pulse wave properties. Lechashchiy Vrach. 2013;13:103-7. (In Russ.) [Драпкина О.М., Корнеева О.Н, Зятенкова Е.В., и др. Розувастатин у пациентов с артериальной гипертензией и дислипидемией: влияние на микроциркуляцию и свойства пульсовой волны. Лечащий Врач. 2013;13:103-7].

2. Drapkina O.M., Korneeva O.N., Sheptulina A.F. Statins and diabetes: risk and benefit. Kardiovaskulyarnaya Terapiya i Profilaktika. 2012;11(6):85-90. (In Russ.) [Драпкина О. М., Корнеева О. Н., Шептулина А.Ф. Статины и сахарный диабет: риск и польза. Кардиоваскулярная Терапия и Профилактика. 2012;11(6):85-90].

3. Ostroumova O.D., Maksimov M.L., Dralova O.V., Ermolaeva A.S. Arterial hypertension and atherosclerosis: how to choose the right antihypertensive drugs? Trudnyy Patsient. 2013;7:16-22. (In Russ.) [Остроумова О.Д., Максимов М.Л., Дралова О.В., Ермолаева А.С. Артериальная гипертония и атеросклероз: как правильно выбрать антигипертензивные препараты? Трудный Пациент. 2013;7:16-22].

4. Drapkina O.M., Dubolazova Yu.V. Combined antihypertensive therapy in the practice of the therapist. Effektivnaya Farmakoterapiya. Kardiologiya i Angiologiya. 2011;4:17-23. (In Russ.) [Драпкина О.М. Дуболазова Ю.В. Комбинированная антигипертензивная терапия в практике терапевта. Эффективная Фармакотерапия. Кардиология и Ангиология. 2011;4:17-23].

5. Volpe M., Tocci G. Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic. Vasc Health Risk Manag. 2012;8:371-80.

6. Toth K. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in highrisk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISkhyperTensive patients). Am J Cardiovasc Drugs. 2014;14(2):137-45.

7. Mancia G., De Backer G., Dominiczak A., et al. Guidelines for the management of Arterial Hypertension: The Task Force for the management of the European Society of Hypertension and of the European Society of Cardiology. J Hypertens. 2007;25(6):1105-87.

8. Pall D., Szanto L., Szabo Z. Triple Combination Therapy in Hypertension: The Antihypertensive Efficacy of treatment with Perindoptil, Amlodipine, and Indapamide SR. Clin Drug Investig. 2014;34(10):701-8

9. Kobalava Zh.D., Kotovskaya Yu.V., Troitskaya E.A. Combined therapy of arterial hypertension: the role of three component combinations. Kardiologiia. 2011;6(51):84-90. (In Russ.) [Кобалава Ж.Д., Котовская Ю.В., Троицкая Е.А. Комбинированная терапия артериальной гипертонии: роль трех компонентных комбинаций. Кардиология. 2011;6(51):84-90].

10. Konradi A.O. Key achievements in combined antihypertensive therapy in recent years. Arterial'naya Gipertenziya. 2012;18(6):1-5. (In Russ.) [Конради А. О. Ключевые достижения в комбинированной антигипертензивной терапии последних лет. Артериальная Гипертензия. 2012;18(6):1-5].

11. Mancia G., Laurent S., Agabiti-Rosei E., et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertension. 2009;27(11):2121-58.

12. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358(9287):1033-41.

13. Patel A., MacMahon S., Chalmers J., et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829-40.

14. Beckett N.S., Peters R., Fletcher A.E., et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98.

15. Dahlof B., Sever P.S., Poulter N.R., et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA): a multicentrerandomised controlled trial. Lancet. 2005;366(9489):895-906.

16. Clavreul N. Optimizing combination therapy for cardiovascular protection: evidence from landmark trials. Medicographia. 2013;35:455-63.

17. Pall D. The antihypertensive efficacy of the perindopril-amlodipine-indapamide combination. J Hypertens. 2012;30(Suppl A):e503. 18. Jr JW. First fixed dose combination perindopril arginine-indapamide-amlodipine: new approach in combination therapy in hypertension. Vnitr Lek. 2014;60(9):801-7.